Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
Categories:
Related Post
AECOM tapped as Los Angeles Olympics infrastructure partner
The Dallas-based firm will help plan and manage venues for the 2028 Olympic and Paralympic…
The 2025 midyear HR checkup: Layoffs, DEI pivots and a ‘tricky’ AI future
A large-scale divestment from people initiatives has left HR teams in an uncomfortable spot, one…
Dominion’s offshore wind project sees slight price hike from tariffs, CEO says
The added expenses will increase customer bills by an average of three cents a month…